Peptide Antibody Conjugates

Monoclonal Antibody (mAb)

There are currently over 1,000 mAbs in development by pharmaceutical and biotech companies.  These mAbs are designed to bind specifically to target cells or proteins.

The global monoclonal antibody market was $48 billion in 2010— with the top 10 mAb therapies commandeering the majority of sales. These include products like Remicade®, Avastin®, Rituxan®, Humira® and Herceptin®.

As a class, monoclonal antibodies hold enormous promise as therapeutics for the treatment of many neurological diseases due to their inherent qualities.  Unfortunately, the BBB prevents mAbs from reaching therapeutically necessary concentrations in brain and thus greatly restricts their treatment potential.  The receptor-mediated transcytosis approach has moved to the forefront of BBB research as it is proving to be a tractable method for achieving relevant concentrations of mAbs to brain parenchyma.

Angiochem Technology: An Opportunity for mAbs

Angiochem is using its proprietary technology to discover and develop new brain penetrant “Peptide-Antibody Conjugates” that reach therapeutic concentrations inside the brain. This technology will allow leaders in the field of biologic drug development to harness the potential of mAbs in the CNS.

These new Peptide-Antibody Conjugates have been engineered to:

• Cross the blood-brain barrier via receptor-mediated transcytosis using the Angiopep moiety
• Retain their affinity to the target receptor and in vivo functionality. 

As a proof-of concept, Angiochem has created a brain penetrant peptide-antibody conjugate of anti-Her2 (ANG4043) that get into the brain in therapeutic concentrations.  > More about ANG4043